

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 December 2011 (01.12.2011)

(10) International Publication Number
WO 2011/149557 A1

- (51) **International Patent Classification:**
A61F 2/44 (2006.01)
- (21) **International Application Number:**
PCT/US201 1/000974
- (22) **International Filing Date:**
27 May 2011 (27.05.2011)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/349,151 27 May 2010 (27.05.2010) US
- (71) **Applicant (for all designated States except US):** **STOUT MEDICAL GROUP, L.P.** [US/US]; 410 East Walnut Street, Suite 8, Perkasi, PA 18944 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** **GREENHALGH, E., Skott** [US/US]; 820 Penlyn Pike, Lower Gwynedd, PA 19002 (US). **ROMANO, John-Paul** [US/US]; 59 Skyline Drive, Chalfont, PA 18914 (US).
- (74) **Agents:** **LEVINE, David, A.** et al; Levine Bagade Han LLP, 2400 Geng Road, Suite 120, Palo Alto, CA 94303 (US).

(81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.1 7(H))

[Continued on next page]

(54) **Title:** SUPPORT DEVICE AND METHOD FOR USE




Fig. 5c

(57) **Abstract:** Devices and methods for orthopedic support are disclosed. The device can have a first rigid section hingedly attached to a second rigid section. The device can be curved or rotated around obstructions along an access path to a target site. The device can be delivered to an intervertebral location in a patient.

WO 2011/149557 A1

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

TITLE OF THE INVENTION

SUPPORT DEVICE AND METHOD FOR USE

E. Skott Greenhalgh

John-Paul Romano

BACKGROUND OF THE INVENTION

1. Field of the Invention

[0001] A device, such as a flexible spinal fusion cage, which can articulate (bend) in such a way that it will be able to be implanted from a lateral approach into L4-L5 and L5-S1 is disclosed.

2. Description of the Related Art

[0002] Typical lateral approach fusion implants (e.g., Discover XLIF, by NuVasive, Inc., San Diego, CA; and the Direct Lateral Interbody Fusion (DLIF) by Medtronic, Inc., Minneapolis, MN) are not able to implant their fusion cages for two reasons.

[0003] First, boney obstacles can impair access. Figures 1a and 1b illustrate the pelvis and lower spine including the Ilium 2, sacrum SI, and lower lumbar vertebrae L3, L4 and L5. Figures 1a and 1b show the challenge of gaining lateral access to the L4-L5 and the L5-S1 intervertebral spaces. The position of the Ilium 2 obstructs the direct lateral access pathway.

[0004] Figure 2 illustrates windows 4a and 4b or channels which some doctors create during implantation. The windows 4a and 4b are created through the Ilium to gain direct line of site access to the L4-L5 and L5-S1 intervertebral spaces, respectively. This is a highly invasive approach, creates significant tissue damage, particularly to the Ilium and surrounding soft tissue, and requires significant surgical skill.

[0005] Second, the steep approach angle (8a for the L4-L5 intervertebral space and 8b for the L5-S1 intervertebral space), as measured from a transverse plane along the approach path (10a for the L4-L5 intervertebral space and 10b for the L5-S1 intervertebral space) of a tissue retractor relative to the location of the fusion site, can cause problems, as illustrated in Figures 3 and 4. The approach paths 10a and 10b pass through the skin surface 12. The tissue retractor used in lateral fusion surgery provides line of site access to the disk space requiring a fusion cage insertion. The tissue retractor holds tissue out of the way of the procedure. The tissue retractor is also used to create a working channel to pass tools through, protect neural tissue, and anchor to

1 the superior and inferior vertebral bodies relative the disk space requiring fusion. The volume
2 within the pelvis and inferior to the dashed demarcation line 6 along a transverse plane is very
3 hard if not impossible to reach with a direct lateral approach due to the Ilium. Even if the
4 retractors are tilted as shown by the demarcation line 6, the ability to insert an implant that is the
5 length of the end plates of the L4 or L5 vertebral bodies would be very difficult due to
6 obstruction of the Ilium among other factors.

7 [0006] Furthermore, with the retractor positioned along the approach path 10a or 10b plane and
8 angled direction, the angle formed between the retractor and the vertebral body end plates would
9 make inserting a monolithic, inflexible fusion cage 14 or implant into the L5-S1 intervertebral
10 space difficult if not virtually impossible due to obstruction of the surrounding hard and soft
11 tissue, as illustrated by Figure 5a. A typical lateral fusion cage or implant width 16 is the width
12 of the end plate 18 along the adjacent disk. The implant 14 can not turn the corner at the pivot
13 point 20 at the lateral and/or anterior edge of the L5-S1 intervertebral space.

14

15

SUMMARY OF THE INVENTION

16 [0007] Support or fixation devices and methods for access, controlling (e.g., steering or rotating,
17 and driving or translating) implants, and modifying the configuration of implants are disclosed.
18 The device can be an implantable fixation device, such as a flexible and/or articulatable fusion
19 cage. The device can articulate and/or bend so the device can make the turn around the L5-S1
20 intervertebral space. The implant can flex and/or articulate. For example, the implant can have
21 hinges and/or be flexible (e.g., have significantly elastic structural components).

22 [0008] Articulation tools are disclosed that can be used to implant the device. The articulation
23 tools can articulate the device and/or allow the device to articulate. For example, the connection
24 between the articulation tool and the implant can bend, flex, steer, or combinations thereof. The
25 articulation tools can be used to debride or clear out the disk space.

26 [0009] An oblique curved access tool or device can be used. The device can be delivered to the
27 intervertebral space along an oblique approach path, not perpendicular to the spine. The oblique
28 approach can provide an access path from lateral skin to the L5-S1 disk space, and can curve
29 tangent to the Ilium. A large working channel through the soft tissue can be created. The
30 oblique access tool can move soft tissue out of the way to create the working channel. The
31 oblique approach can reduce the access-tool-to-disk-space approach angle.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

BRIEF DESCRIPTION OF THE DRAWINGS

[0010] Figures 1a and 1b are anterior and lateral views, respectively, of the lower lumbar and sacral spine and pelvis with the Ilium shown in phantom lines in Figure 1b.

[0011] Figure 2 is a lateral view of the lower lumbar spine with windows cut through the Ilium.

[0012] Figures 3 and 4 are anterior and lateral views, respectively, of the lower spine and pelvis along with approach paths into the intervertebral spaces.

[0013] Figure 5a is an anterior close-up view of the lower spine and pelvis with an approach of a monolithic implant.

[0014] Figure 5b illustrates a variation of the implantable device.

[0015] Figures 5c and 5d illustrate a variation of a method of delivering the device of Figure 5b into the L5-S1 space.

[0016] Figures 6 through 8 are anterior, perspective and lateral views, respectively, of a variation of the approach path for delivering the implant into the intervertebral space.

[0017] Figures 9a through 9d illustrate variations of the device in various configurations. An x-axis, y-axis and z-axis are also shown for orientation with the x-axis disposed along the longitudinal axis of the device.

[0018] Figures 10a and 10b illustrate various configurations of a variation of the device in a steering tube with the tube shown as see-through for illustrative purposes.

[0019] Figures 10c through 10e illustrate various configurations of a variation of the device on steering rails attached to the lateral outside of the device.

[0020] Figures 11a through 11c illustrate various configurations of a variation of the device on a steering rail attached to the inside of the device.

[0021] Figures 12a through 12f are cross-sections of various steering rails, or along the length of the same steering rail.

[0022] Figure 13 illustrates a method for deploying the device into the L5-S1 intervertebral space.

[0023] Figures 14a and 14b illustrate various configurations of a variation of the device in a steering slide.

[0024] Figures 14a and 14b are top and side views of a variation of the device with parallel hinges.

- 1 [0025] Figure 15 is a top view of a variation of the device with non-parallel hinges.
- 2 [0026] Figures 16a and 16b are side views of a variation of the device in straight or flat and
3 flexed configurations, respectively.
- 4 [0027] Figures 17a through 17d are side views of variations of the device.
- 5 [0028] Figures 18 and 19 are perspective views showing the orientation of variations of living
6 hinges within devices.
- 7 [0029] Figures 20a through 20c are perspective, top and front views, respectively, of a variation
8 of the device in a straight or flat configuration.
- 9 [0030] Figures 21a through 21c are perspective, top and front views, respectively, of the device
10 of Figures 20a through 20c in an articulated configuration.
- 11 [0031] Figures 22a through 22c are perspective, top and front views, respectively, of a variation
12 of the device in a straight or flat configuration.
- 13 [0032] Figures 23a through 23c are perspective, top and front views, respectively, of the device
14 of Figures 22a through 22c in an articulated configuration.

15

16

DETAILED DESCRIPTION

- 17 [0033] Support or fixation devices and methods for access, controlling (steering) implants, and
18 modifying implants are disclosed. The device can be an implantable fixation device, such as a
19 flexible fusion cage. The device can be delivered into an intervertebral space, for example, to
20 provide structural support between the adjacent vertebrae. The device can fuse the vertebra
21 adjacent to the specific intervertebral space. A discectomy can be performed at the target
22 implant site before or during delivery of the implant.
- 23 [0034] Figure 5b illustrates that the implantable device 14 can have first, second, third, and
24 fourth segments 22a through 22d. Each of the segments 22a, 22b, 22c, and 22d can be attached
25 to the adjacent segment at a flex point or articulatable hinge 24a, 24b, and 24c, respectively. The
26 device 14 can articulate and/or bend at the hinges 24.
- 27 [0035] Figures 5c and 5d illustrate that the device 14 can be delivered into the L5-S1
28 intervertebral space. The device 14 can make the turn around the L5-S1 intervertebral space,
29 such as at the pivot point 20, by articulating or flexing.
- 30 [0036] Figures 6 through 8 shows illustrate a curved implant pathway or approach path 10c. An
31 articulation tool can be used to push (e.g., impact), pull, control or combinations thereof, the

1 implant 14. The implant 14 can articulate and/or flex during delivery. The implant can have
2 single or multiple hinges, a flexible shaft, laser slots (e.g., in a tube to act as hinges) or
3 combinations thereof.

4 [0037] The approach path 10c can be tangential to the medial surface of the Ilium along a
5 portion of the length of the approach path 10c. A portion of the length of the approach path 10c
6 can be linear and a portion of the length of the approach path 10c can be curved. The entire
7 approach path 10c can be linear or curved. A portion of the length of the approach path 10c can
8 track (i.e., follow the same shape of) the medial surface of the Ilium. The approach path 10c can
9 contact the medial surface of the Ilium 2. The approach path 10c can be non-perpendicular or
10 perpendicular to the longitudinal axis 27 of the spine where the approach path 10c enters the
11 intervertebral space L4-L5 or L5-S1 .

12 [0038] The approach-Ilium gap 26 can be measured between the approach path 10c and the
13 closest medial surface of the Ilium 2. The approach-Ilium gap 26 can be perpendicular to the
14 approach path 10c and the Ilium 2, for example when the approach path 10c is tracking the
15 medial surface of the Ilium 2. The approach-Ilium gap 26 can be from about 0 mm to about 15
16 mm along the length of the approach path 10c where the approach path is tracking the medial
17 surface of the Ilium 2, more narrowly from about 0 mm to about 10 mm, yet more narrowly from
18 about 2 mm to about 8 mm.

19 [0039] The approach path 10c can be curved in all three dimensions (e.g., in the transverse
20 plane, sagittal plane and coronal plane), or any combination thereof and straight in the remaining
21 dimensions.

22 [0040] Figure 9a through 9d illustrate that variations of hinges 24a and 24b between the
23 segments 22a, 22b and 22c can allow the implant 14 to articulate. The implant 14 can have
24 controlled angulation or articulation (i.e., with discrete, defined built-in stopping points or stops)
25 or free angulation or articulation (i.e., with no stops).

26 [0041] Figure 9a illustrates that the hinges 24a and 24b can be oriented in parallel with the z-
27 axis. The hinges can have a single degree of rotational freedom. The segments 24, 24b and 24c
28 can articulate by rotating about the z-axis with respect to each other. The hinges 24a and 24b
29 can be near the top (as shown), near the bottom, in the middle with respect to the y-axis, or
30 combinations thereof of the device 14.

1 [0042] Figure 9b illustrates that the hinges 24a and 24b can be oriented in parallel with the x-
2 axis. The segments 24, 24b and 24c can articulate by rotating about the x-axis with respect to
3 each other. The hinges 24a and 24b can be near the front (as shown), near the rear, in the middle
4 with respect to the z-axis, or combinations thereof of the device 14.

5 [0043] Figure 9c illustrates that the hinges 24a and 24b can be oriented in parallel with the y-
6 axis. The segments 24, 24b and 24c can articulate by rotating about the y-axis with respect to
7 each other. The hinges 24a and 24b can be near the front (as shown), near the rear, in the middle
8 with respect to the z-axis, or combinations thereof of the device 14.

9 [0044] Figure 9d illustrates that the hinges 24a and 24b can be ball-in-socket hinges allowing
10 three rotational degrees of freedom, or a combination of the three hinges described in Figures 9a
11 through 9c, allowing two or three degrees of freedom. The segments 24, 24b and 24c can
12 articulate by rotating about the x-axis, and/or y-axis, and/or z-axis with respect to each other.
13 The hinges 24a and 24b can be near the front (as shown), near the rear, in the middle with
14 respect to the z-axis, near the top, near the bottom, in the middle with respect to the y-axis (as
15 shown), or combinations thereof of the device 14.

16 [0045] The first hinge 24a can be located in a different location and/or with a different than the
17 second hinge 24b. For example, the first hinge 24a can be oriented in parallel with the z-axis,
18 allow rotation about the z-axis and be located near the top of the device 14, and the second hinge
19 24b can be oriented in parallel with the x-axis, allow rotation about the x-axis, and be located
20 near the middle of the device 14 with respect to the z-axis.

21 [0046] Figures 10a and 10b illustrate that the device 14 can have an outer steering sheath or tube
22 28. The device 14 can be fixed to the steering tube 28 or can slide along the steering tube 28.
23 The steering tube 28 can be articulatable and/or flexible, as shown by the arrow in Figure 10b
24 and the various configurations of the tube 28 between Figures 10a and 10b. The articulation or
25 flexion of the steering tube 28 can be controlled, for example by delivering controlled tension to
26 tensile control wires in the walls of the steering tube 28.

27 [0047] The steering tube 28 can be positioned at the target deployment site. For example, the
28 steering tube 28 can be placed in the intervertebral space and can remain in the intervertebral
29 space post-surgery, or the steering tube 28 can be removed from the intervertebral space and the
30 device 14 can be deployed from the tube 28 and the device 14 can be left in the intervertebral
31 space.

1 [0048] Also for example, the distal end of the steering tube 28 can be positioned at the entrance
2 to the intervertebral space and/or rested on the inferior and/or superior vertebral body end plate
3 adjacent to the target intervertebral space. The device 14 can then be pushed (e.g., by a plunger)
4 out of the steering tube and into the intervertebral space. The steering tube 28 does not have to,
5 but can, enter the intervertebral space.

6 [0049] Figures 10c through 10d illustrate that the device 14 can have one or more exterior
7 steering rails, tracks or wires 30a and 30b, such as guidewires. The rails 30a and 30b can
8 slidably or fixedly and releasably engage the external surface of the segments 22 of the device
9 14. For example, the rails can pass through slots, guides, collars, cuffs or combinations thereof
10 on the exterior of the segments 22. The slots, guides, collars, cuffs or combinations thereof,
11 and/or the rails 30a and 30b can be coated or covered with a low-friction (e.g., PTFE) or high-
12 friction (e.g., knurled or toothed surface texturing) material or surface treatment or texture,
13 including any of the materials listed herein. The steering rails 30a and 30b can be steered or
14 manipulated by applying a tensile force to tensile cables within the rails, as shown by the arrows
15 in Figures 10d and 10e, and the flexing from Figure 10c to 10d. The rails 30a and 30b can be
16 pre-formed to a specific shape and can be substituted for other rails 30a and 30b that can be pre-
17 formed to a different shape to change the direction of delivery.

18 [0050] Figures 11a through 11c illustrates that the device 14 can have one or more interior
19 steering rails, guide, tracks or wires 30, such as guidewires. The rails 30 can be positioned
20 through the center or interior of one or more segments 22 of the device 14. The rail 30 can
21 slidably or fixedly and releasably engage an internal surface, such as through a longitudinal
22 guide port or channel 32, of the segments 22 of the device 14. For example, ports or channels
23 can extend longitudinally through the segments 22 of the device 14. The channels, and/or the
24 rail 30 can be coated, covered or collared, such as with a low-friction (e.g., PTFE) or high-
25 friction (e.g., knurled or toothed surface texturing) material or surface treatment or texture,
26 including any of the materials listed herein. The steering rail 30 can be steered or manipulated
27 by applying a tensile force to tensile cables within the rail 30, as shown by the flexing from
28 Figure 11a to 11c. The rail 30 can be pre-formed to a specific shape and can be substituted for
29 one or more other rails 30 that can be pre-formed to a different shape to change the direction of
30 delivery.

1 [0051] The distal ends of the internal and/or external steering rail or rails 30 can be positioned at
2 the target deployment site. For example, the steering rails 30 can be placed in the intervertebral
3 space and can remain in the intervertebral space post-surgery, or the steering rails 30 can be
4 removed from the intervertebral space and the device 14 can be deployed from the rails 30 and
5 the device 14 can be left in the intervertebral space.

6 [0052] Also for example, the distal end of the steering rails 30 can be positioned at the entrance
7 to the intervertebral space and/or rested on the inferior and/or superior vertebral body end plate
8 adjacent to the target intervertebral space. The device 14 can then be pushed (e.g., by a plunger)
9 out of the steering rails 30 and into the intervertebral space. The steering rails 30 do not have to,
10 but can, enter the intervertebral space.

11 [0053] Figures 12a through 12f illustrate cross-sections of various rails 30, or at various lengths
12 along the same rail 30. Figure 12a illustrates that the cross-section of the steering rail 30 can be
13 circular. Figure 12b illustrates that the cross-section of the steering rail 30 can be oval. Figure
14 12c illustrates that the cross-section of the steering rail 30 can be multi-ovular (i.e., having a
15 union of two or more ovals with the same major axis). Figure 12d illustrates that the cross-
16 section of the steering rail 30 can be the union of rectangles intersecting at right (or another)
17 angle, such as a plus-sign. Figure 12e illustrates that the cross-section of the steering rail 30 can
18 be hexagonal. Figure 12f illustrates that the cross-section of the steering rail 30 can be
19 rectangular or square with sharp or rounded (chamfered) edges. The cross-section of the steering
20 rail 30 can be triangular, pentagonal, heptagonal, or octagonal. The steering rail 30, whether
21 internal or external to the device 14, can deliver torque around the longitudinal and/or transverse
22 axes of the device. The steering rail 30 can have various cross sections at various lengths along
23 the rail 30. The steering rail 30 can guide, pitch, yaw and roll the device 14 into a desired
24 orientation or indication. The device 14 can be delivered with one or more internal and/or
25 external rails 30 and/or a sheath 28 or neither.

26 [0054] Figure 13 illustrates a device 14 that can be attached to a deployment tool having a
27 controller handle 34 controllably attached to the internal steering rail 30. The internal steering
28 rail 30 can pass through the device 14. The steering rail 30 can be fixedly attached to the device
29 14 during the delivery and articulation of the device 14. The device can be steered along or
30 tracking the medial surface of the Ilium 2. The device 14 can then be positioned adjacent to the

1 target site (e.g., the L5-S1 intervertebral space). The deployment tool can then release the device
2 14 from the steering rail 30 and push the device 14 into the target site.

3 **[0055]** Figures 14a and 14b illustrate that the device 14 can be delivered by being pushed along a
4 steering horn, boot, or slide 36. The slide 36 can be similar to the steering tube 28, except that at
5 least one wall of the slide 36 can be missing or open (e.g., the top wall is not present in the
6 variation of the slide shown) compared with the steering tube 28. The missing wall can be
7 completely open or replaced by one or more steering rails 30. The slide 36 can be used similar to
8 the steering rails 30 and/or steering tube 28. The slide 36 can be steered, flexed or articulated by
9 applying a tensile force to tensile cables within the rails, as shown by the arrow in Figure 14b,
10 and the flexing from Figure 14a to 14b.

11 **[0056]** Figures 15a and 15b illustrate that the device 14 can have six segments 22a through 22f
12 and five hinges 24a through 24e. The segments 22 can be attached to adjacent segments 22 by
13 one or more hinges, tension or steering rails or wires, screws, pins, or combinations thereof.
14 The hinges 24 can be pins. The segments 22 can be chained together. The segments 22 can be
15 identical to each other except for the distal-most segment 22a and the proximal-most segment
16 22f. The segments 22 or links can be box-shaped. The hinges 24, such as the pins, can be
17 parallel to all or some of the other hinges 24.

18 **[0057]** Figure 16 illustrates that the hinges 24 can be at acute angles to all or some of the hinges
19 24. The hinges 24 can be at hinge angles 38 with respect to each other. The hinge angle 38 can
20 be measured between the hinge longitudinal axis 40 and the device longitudinal axis 42. The
21 hinge angles 38 can be from about 80° to about 150°, more narrowly from about 90° to about
22 135°, yet more narrowly from about 95° to about 110°.

23 **[0058]** The device 14 can be translated and/or rotated by a handle 34 that can be removably
24 attached to the device 14. The handle 34 can be screwed and/or snapped directly into the
25 proximal end of the device 14, such as into the proximal-most segment 22. The handle 34 can
26 compress, such as by grabbing or pinching, the proximal end of the device 14. The handle 34
27 can be a pusher, plunger, ram, or combinations thereof. The handle 34 and/or remainder of the
28 deployment tool can be rigid and/or flexible or articulatable. For example, hinged similar to the
29 device 14.

30 **[0059]** The segments 22 are not necessarily connected to each other by hinges. The segments 22
31 can be delivered to the target site individually, or as an unattached line of segments 22.

1 [0060] The device 14 can be cylindrical and flexible. The implantable device 14 can be fully
2 flexible all the time. The device 14 can be mechanically stabilized by the deployment tool,
3 steering wires, sheaths, tubes and guides. For example, the tools, wires, sheaths, tubes and
4 guides can provide column stability to press the device 14 into the target site (e.g., intervertebral
5 disc space).

6 [0061] The device 14 can flexible, and then locked with a tension or steering wire to stop
7 rotational motion of the hinges once the device is delivered to and oriented within the target site.
8 The tension wire could be tightened, for example by being tensioned by a nut to create higher
9 friction in each hinge 24.

10 [0062] Figures 17a through 17f illustrate that the device 14 can have a living hinge 44. The
11 living hinge 44 is a length of decreased rigidity and increased flexing within the body of the
12 device 14. The living hinge 44 can be formed around slots and continuous segments of
13 otherwise tough, durable material. The living hinge 44 can be defined be narrowing or thinning
14 in the body of the device 14, such that the narrowing is sufficient to provide flexibility under
15 reasonable torque. For example, the thickness of the unitary body of the device 14 at the living
16 hinge 44 can be narrowed by more than about 85%, or more than about 90%, or more than about
17 95%, or more than about 97%», or more than about 98.5%. The living hinge 44 can have one or
18 more repeated thinnings along the length of the device 14, as shown in Figures 17a through 17f.

19 [0063] Figures 17a and 17b illustrate that the device 14 bends at the living hinge 44. The living
20 hinges 44 can be made to control the bend and direction of the device 14. The outer surface of
21 the device 14 along the living hinge 44 can be smooth, for example providing low-friction
22 surface for sliding over bone.

23 [0064] Figures 17a and 17b illustrate that the living hinge 44 can be along the bottom of the
24 implant device 14. Figure 17c illustrates that the living hinge 44 can be along the top of the
25 device 14. Figure 17d illustrates that the living hinge 44 can be through the middle or central
26 axis of the device 14. Figure 17e illustrates that the living hinge 44 is discontinuous and on
27 opposite sides of the center of the device 44. Figure 17f illustrates that the living hinge 44 is at
28 an angle with respect to the longitudinal axis of the device 14, starting near the bottom of the
29 device 14 and ending near the top of the device 14.

1 [0065] Figure 18 illustrates that the living hinge 42 can be at a non-zero angle to the central
2 longitudinal axis 42 of the device 14. A first length of the living hinge 42 can be at a non-zero
3 angle to a second length of the living hinge 44.

4 [0066] Figure 19 illustrates that the living hinge 44 can be curved. The living hinge 44 can
5 curve around the central longitudinal axis 42 of the device 14.

6 [0067] Figures 20a through 20c illustrate that the device can have three segments 22a, 22b and
7 22c connected by two hinges 24a and 24b. The device longitudinal axis 42 can be straight or can
8 have a longitudinal radius of curvature 46. The longitudinal radius of curvature 46 can be from
9 about 3 cm to about 100 cm, more narrowly from about 5 cm to about 20 cm, yet more narrowly
10 from about 7 cm to about 15 cm, for example about 15 cm, also for example about 10 cm.

11 [0068] The device 14 can have an anterior taper angle 48. The taper angle can be measured
12 between the plane of the top surface and the plane of the bottom surface of the device 14. The
13 taper angle can be from about 0° (i.e., parallel top and bottom planes) to about 45°, more
14 narrowly from about 2° to about 20°, yet more narrowly from about 4° to about 10°.

15 [0069] One or more segments have through-ports 50. The through-ports 50 can extend partially
16 or completely from the top to the bottom surface of the device 14. The through-ports can be
17 filled with a matrix or material to promote bone ingrowth, such as BMP or other materials listed
18 herein.

19 [0070] The device 14 can have a surface coating or texturing on the top, and/or bottom, and/or
20 side surfaces, such as lateral teeth 52, longitudinal or angled teeth, knurling, a coating or matrix
21 to promote bone ingrowth, or combinations thereof.

22 [0071] The device 14 can have hinge teeth 54. The hinge teeth 54 can slide by adjacent hinge
23 teeth to increase lateral stability during articulation and increase range of motion (e.g., a hinge
24 tooth 54 on one segment 22 can slide into the gap between hinge teeth 54 on the adjacent
25 segment 22 during articulation of the device 14).

26 [0072] One or more tension and/or steering wires can be inserted and/or tensioned through guide
27 ports or channels 32a and 32b. The guide channels 32a and 32b can extend longitudinally
28 through some or all of the segments 22.

29 [0073] Figures 21a through 21c illustrate that device 14 can articulate. The segments 22 can
30 rotate with respect to each other about the hinges 24, as shown by arrows.

1 [0074] Figures 22a through 22c illustrate that some or all of the distal-most segments 22a
2 through 22d can be identical. Segments 22 can be added or removed from the device 14, before
3 during or after deployment to the target site, to increase or decrease the length of the device 14 to
4 best fit the target site. The false hinge 24' can be a hinge component that is not attached to the
5 other half of the hinge 24. The hinges 24 can snap together and apart. The articulation of each
6 segment 22 can be limited by the interference fit of a rotational stop 58 on the top and bottom of
7 the adjacent segment 22.

8 [0075] The device 14 can have a deployment tool interface, such as the lateral hole 56, for
9 attaching to the deployment tool.

10 [0076] Figures 23a through 23c illustrate that a tensioning or steering wire or rail 30 can be
11 deployed through the channels 32 on each segment. The wire 30 can then be tensioned to
12 articulate and/or lock the device 14 in an articulated configuration.

13 [0077] Any or all elements of the device and/or other devices or apparatuses described herein
14 can be made from, for example, a single or multiple stainless steel alloys, nickel titanium alloys
15 (e.g., Nitinol), cobalt-chrome alloys (e.g., ELGILOY® from Elgin Specialty Metals, Elgin, IL;
16 CONICHROME® from Carpenter Metals Corp., Wyomissing, PA), nickel-cobalt alloys (e.g.,
17 MP35N® from Magellan Industrial Trading Company, Inc., Westport, CT), molybdenum alloys
18 (e.g., molybdenum TZM alloy, for example as disclosed in International Pub. No. WO
19 03/082363 A2, published 9 October 2003, which is herein incorporated by reference in its
20 entirety), tungsten-rhenium alloys, for example, as disclosed in International Pub. No. WO
21 03/082363, polymers such as polyethylene terephthalate (PET)/polyester (e.g., DACRON®
22 from E. I. Du Pont de Nemours and Company, Wilmington, DE), polypropylene, (PET),
23 polytetrafluoroethylene (PTFE), expanded PTFE (ePTFE), polyether ketone (PEK), polyether
24 ether ketone (PEEK), poly ether ketone ketone (PEKK) (also poly aryl ether ketone ketone),
25 nylon, polyether-block co-polyamide polymers (e.g., PEBAX® from ATOFINA, Paris, France),
26 aliphatic polyether polyurethanes (e.g., TECOFLEX® from Thermedics Polymer Products,
27 Wilmington, MA), polyvinyl chloride (PVC), polyurethane, thermoplastic, fluorinated ethylene
28 propylene (FEP), absorbable or resorbable polymers such as polyglycolic acid (PGA), polylactic
29 acid (PLA), polycaprolactone (PCL), polyethyl acrylate (PEA), polydioxanone (PDS), and
30 pseudo-polyamino tyrosine-based acids, extruded collagen, silicone, zinc, echogenic, radioactive,
31 radiopaque materials, a biomaterial (e.g., cadaver tissue, collagen, allograft, autograft, xenograft,

1 bone cement, morselized bone, osteogenic powder, beads of bone) any of the other materials
2 listed herein or combinations thereof. Examples of radiopaque materials are barium sulfate, zinc
3 oxide, titanium, stainless steel, nickel-titanium alloys, tantalum and gold.

4 [0078] Any or all elements of the device and/or other devices or apparatuses described herein,
5 can be, have, and/or be completely or partially coated with agents and/or a matrix a matrix for
6 cell ingrowth or used with a fabric, for example a covering (not shown) that acts as a matrix for
7 cell ingrowth. The matrix and/or fabric can be, for example, polyester (e.g., DACRON® from E.
8 I. Du Pont de Nemours and Company, Wilmington, DE), polypropylene, PTFE, ePTFE, nylon,
9 extruded collagen, silicone or combinations thereof.

10 [0079] The device and/or elements of the device and/or other devices or apparatuses described
11 herein and/or the fabric can be filled, coated, layered and/or otherwise made with and/or from
12 cements, fillers, glues, and/or an agent delivery matrix known to one having ordinary skill in the
13 art and/or a therapeutic and/or diagnostic agent. Any of these cements and/or fillers and/or glues
14 can be osteogenic and osteoinductive growth factors.

15 [0080] Examples of such cements and/or fillers includes bone chips, demineralized bone matrix
16 (DBM), calcium sulfate, coralline hydroxyapatite, biocoral, tricalcium phosphate, calcium
17 phosphate, polymethyl methacrylate (PMMA), biodegradable ceramics, bioactive glasses,
18 hyaluronic acid, lactoferrin, bone morphogenic proteins (BMPs) such as recombinant human
19 bone morphogenetic proteins (rhBMPs), other materials described herein, or combinations
20 thereof.

21 [0081] The agents within these matrices can include any agent disclosed herein or combinations
22 thereof, including radioactive materials; radiopaque materials; cytogenic agents; cytotoxic
23 agents; cytostatic agents; thrombogenic agents, for example polyurethane, cellulose acetate
24 polymer mixed with bismuth trioxide, and ethylene vinyl alcohol; lubricious, hydrophilic
25 materials; phosphor cholene; anti-inflammatory agents, for example non-steroidal anti-
26 inflammatories (NSAIDs) such as cyclooxygenase-1 (**COX-1**) inhibitors (e.g., acetylsalicylic
27 acid, for example ASPIRIN® from Bayer AG, Leverkusen, Germany; ibuprofen, for example
28 ADVIL® from Wyeth, Collegeville, PA; indomethacin; mefenamic acid), **COX-2** inhibitors
29 (e.g., VIOXX® from Merck & Co., Inc., Whitehouse Station, NJ; CELEBREX® from
30 Pharmacia Corp., Peapack, NJ; **COX-1** inhibitors); immunosuppressive agents, for example
31 Sirolimus (RAPAMUNE®, from Wyeth, Collegeville, PA), or matrix metalloproteinase (MMP)

1 inhibitors (e.g., tetracycline and tetracycline derivatives) that act early within the pathways of an
2 inflammatory response. Examples of other agents are provided in Walton et al, Inhibition of
3 Prostaglandin E₂ Synthesis in Abdominal Aortic Aneurysms, *Circulation*, July 6, 1999, 48-54;
4 Tambiah et al, Provocation of Experimental Aortic Inflammation Mediators and Chlamydia
5 Pneumoniae, *Brit. J. Surgery* 88 (7), 935-940; Franklin et al, Uptake of Tetracycline by Aortic
6 Aneurysm Wall and Its Effect on Inflammation and Proteolysis, *Brit. J. Surgery* 86 (6), 771-775;
7 Xu et al, Spl Increases Expression of Cyclooxygenase-2 in Hypoxic Vascular Endothelium, *J.*
8 *Biological Chemistry* 275 (32) 24583-24589; and Pyo et al, Targeted Gene Disruption of Matrix
9 Metalloproteinase-9 (Gelatinase B) Suppresses Development of Experimental Abdominal Aortic
10 Aneurysms, *J. Clinical Investigation* 105 (11), 1641-1649 which are all incorporated by
11 reference in their entireties.


12 [0082] Any elements described herein as singular can be pluralized (i.e., anything described as
13 "one" can be more than one). Any species element of a genus element can have the
14 characteristics or elements of any other species element of that genus. The above-described
15 configurations, elements or complete assemblies and methods and their elements for carrying out
16 the invention, and variations of aspects of the invention can be combined and modified with each
17 other in any combination.

CLAIMS

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

We claim:

1. A biological implant device for providing orthopedic support comprising:
 - a first rigid section with a first top plate and a first bottom plate; and
 - a second rigid section with a second top plate and a second bottom plate;wherein the first rigid section is rotatably attached to the second rigid section, and wherein the top and bottom plates are configured to interface with hard tissue.
2. A method for inserting an implant to a target site between a first vertebra and a second vertebra comprising:
 - inserting a first rigid section of the implant into the target site,
 - rotating a second rigid section of the implant with respect to the first rigid section,wherein the first rigid section is hingedly attached to the second rigid section; and
 - inserting the second rigid section of the implant into the target site.



NOT INVENTION


Fig. 2

NOT INVENTION

Fig. 1b


NOT INVENTION

Fig. 1a



NOT INVENTION

Fig. 3



NOT INVENTION

Fig. 4




Fig. 5c




Fig. 5d

NOT INVENTION
Fig. 5a




Fig. 5b




Fig. 6




Fig. 7




Fig. 8




Fig. 9a




Fig. 9b




Fig. 9c




Fig. 9d




Fig. 10a




Fig. 10b




Fig. 10c




Fig. 10d




Fig. 10e




Fig. 11a




Fig. 11b




Fig. 11c



Fig. 12a




Fig. 12b



Fig. 12c



Fig. 12d



Fig. 12e



Fig. 12f




Fig. 13




Fig. 14a




Fig. 14b




Fig. 15a




Fig. 15b




Fig. 16




Fig. 17a




Fig. 17b




Fig. 17c




Fig. 17d




Fig. 17e



Fig. 17f




Fig. 18




Fig. 19




Fig. 20a




Fig. 20b




Fig. 20c




Fig. 21a




Fig. 21b







Fig. 21c






Fig. 23a




Fig. 23b




Fig. 23c

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US201 1/000974

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61 F 2/44 (201 1.01)
USPC - 623/17.16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8) - A61 F 2/44, 2/46 (201 1.01)
 USPC - 623/17.1 1, 17.15, 17.16

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PatBase

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| X | US 2009/0182431 A1 (BUTLER et al) 16 July 2009 (16.07.2009) entire document | 1 |
| X | US 2009/0054991 A1 (BIYANI et al) 26 February 2009 (26.02.2009) entire document | 2 |
| A | US 2008/0312743 A1 (VILA et al) 18 December 2008 (18.12.2008) entire document | 1-2 |

Further documents are listed in the continuation of Box C.

| | |
|---|--|
| * Special categories of cited documents: | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| "A" document defining the general state of the art which is not considered to be of particular relevance | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| "E" earlier application or patent but published on or after the international filing date | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "&" document member of the same patent family |
| "O" document referring to an oral disclosure, use, exhibition or other means | |
| "P" document published prior to the international filing date but later than the priority date claimed | |

Date of the actual completion of the international search
 15 September 2011

Date of mailing of the international search report
22 SEP 2011

Name and mailing address of the ISA/US
 Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
 P.O. Box 1450, Alexandria, Virginia 22313-1450
 Facsimile No. 571-273-3201

Authorized officer:
 Blaine R. Copenheaver
PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774